Biomarkers in Autism of Aripiprazole and Risperidone Treatment (BAART)
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
The Biomarkers in autism of aripiprazole and risperidone treatment (BAART) project will
provide evidence-based guidance in the selection and monitoring of drug treatment of autism.
BAART involves 3 academic centers across South Carolina. Although the FDA has approved use of
the antipsychotic drug risperidone for irritability associated with autistic disorder, a
moderate response rate in pivotal clinical trials and concerns over tolerability and weight
gain can force clinicians to select alternative drug treatments for which evidence-based
support is sparse.